Tumor Board: Clinical Integration of Molecular Profiling in Glioma—Transforming the Use of Targeted TherapyJune 5th 2026The experts unpack molecular profiling for adult and pediatric low- and high-grade gliomas, including a discussion of targeted therapies for MAPK pathway, IDH, and H3K27M altered disease.
Cases and Conversations™: Next-Generation Pathology Advances and Considerations for Precision Care in Non–Small Cell Lung CancerMay 6th 2026
Medical Crossfire® — From Diagnostic Dilemmas to Potential Treatment Breakthroughs: Exploring Novel Targets for Extrapulmonary Neuroendocrine CarcinomasApril 29th 2026
Medical Crossfire®: Optimizing ESR1 Mutation Detection and Next-Generation Endocrine Therapy Integration in HR+/HER2– Breast CancerApril 28th 2026
From Molecular Insights to Clinical Impact: Translating the Latest Advances in Menin Inhibitors Into PracticeApril 27th 2026
Medical Crossfire®: Advancing Personalized Care in TNBC—Integrating Biomarkers, Clinical Evidence, and Emerging TherapiesApril 24th 2026
Medical Crossfire® Expanding Options, Evolving Challenges in Advanced HR+/HER2– Breast Cancer: How Experts Apply the Latest DataApril 23rd 2026
Show Me the Data: Translating Clinical and Practice-Based Evidence on Oral SERDs Into Everyday Care for HR+/HER2– Metastatic Breast Cancer April 21st 2026
OncoBytes Adaptive Learning Pathways: Personalizing Treatment Plans to Optimize Adjuvant Therapy in Early-Stage HR+/HER2– Breast CancerApril 20th 2026
Live Tumor Board: Squamous Cell Carcinoma of the Head & Neck - Post-CRT Decisions in the Locally Advanced SettingApril 17th 2026
Medical Crossfire®: PD-L1 Inhibition in Advanced Cutaneous Squamous Cell Carcinoma — Mechanistic Rationale and Clinical ApplicationApril 15th 2026
Medical Crossfire®: Translating Risk Into Action—Redefining Adjuvant Strategies for Early HR+/HER2– Breast CancerApril 14th 2026
Medical Crossfire®: Redefining Frontline and Maintenance Strategies in HER2+ Metastatic Breast CancerApril 10th 2026
Shifting the Paradigm in Small Cell Lung Cancer: Targeting Tumor Biology to Transform Patient OutcomesApril 9th 2026
Coffee Talk: Charting New Pathways With HER2 and TROP2 Therapies – From Early to Advanced Breast CancerApril 7th 2026
Facilitating Precision Pathways: Surgical Considerations in Breast Cancer for Tackling Barriers to Genetic Testing and Targeted TherapiesApril 3rd 2026
Show Me the Data®: How Today’s Evidence Is Shaping Tomorrow’s Management and Prophylaxis of Chronic GVHDMarch 31st 2026
Show Me the Data™—Closing Clinical Gaps in Gastric and Esophageal Cancer: Advancing Targeted Treatment Strategies Across the Care ContinuumMarch 13th 2026
Show Me the Data™: Post-TKI Sequencing in EGFR-Mutated NSCLC—Optimizing Current Strategies and Preparing for New Treatment ModalitiesMarch 10th 2026
Medical Crossfire®: Breakthroughs in Non–Muscle-Invasive Bladder Cancer: Advancing Patient Care Through Innovation in TreatmentMarch 6th 2026
Show Me the Data™: Incorporating the Latest Advances in Immunotherapy and EGFR-Targeted Treatments for Resectable Early-Stage NSCLCMarch 3rd 2026
Cases and Conversations™: Navigating the New Immunotherapy Era in Squamous Cell Anal CarcinomaFebruary 27th 2026
Expert Illustrations & Commentaries: Translating the Science of Bispecific Antibodies in Solid Tumors – From Mechanisms to Emerging DataFebruary 26th 2026
Cases & Conversations™: Unmasking Epithelioid Sarcoma – Enhancing Early Diagnosis and Multidisciplinary CareFebruary 24th 2026
“D” is for Diagnosis: Decoding a Difficult Thoracic Malignancy—Piecing Together a Rare Diagnosis, Preparing for Tomorrow’s TreatmentsFebruary 12th 2026